Clinical trial · Observational
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies
NCT06208878CI-TRIAL-00093638enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non Interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Non Interventional
- description
- All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.
- interventionNames
- Other: Non Interventional
Primary outcomes (1)
- measure
- The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
- timeFrame
- 15 years
- description
- The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.
Secondary outcomes (1)
- measure
- The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document. * Must have received CRISPR CAR T cellular therapy. Exclusion Criteria: * There are no specific exclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.